Oncolys BioPharma Inc. [4588.T]
TOKYO, May 08 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) reported non-operating income and expenses for its fiscal first quarter ending March 31, 2026.
For the period from January 01, 2026, to March 31, 2026, the company recorded total non-operating income of ¥12 million, primarily due to foreign exchange gains from revaluation of foreign-currency-denominated assets and interest received. Conversely, during the same period, the firm incurred total non-operating expenses amounting to ¥5 million.
These expenses included stamp duties related to the exercise of subscription rights and interest payments. The impact of these non-operational items on performance is detailed in the company’s interim condensed consolidated unaudited results released on May 08, 2026.
🟢 Confidence: High AI-translated content.